Further genomic data analysis indicated that MUC16 mutations are prevalent in melanoma patients, with such variations closely linked to increased TMB and improved prognosis, potentially by activating immune pathways and enhancing T cell memory functions (118). Here, MUC16 is linked to melanoma.